Patrick J. Heron - Sep 12, 2024 Form 3 Insider Report for MBX Biosciences, Inc. (MBX)

Role
Director, 10%+ Owner
Signature
/s/ Richard Bartram, attorney-in-fact
Stock symbol
MBX
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
3
Date filed
9/12/2024, 07:20 PM
Previous filing
Sep 10, 2024
Next filing
Sep 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MBX Series A Convertible Preferred Stock Sep 12, 2024 Common Stock 1.57M By Frazier Life Sciences X, L.P. F1, F2
holding MBX Series B Convertible Preferred Stock Sep 12, 2024 Common Stock 2.35M By Frazier Life Sciences X, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.
F2 These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Remarks:

Exhibit 24 - Power of Attorney